Treatment not superior to placebo after endpoints of 10 and 26 weeks, reports MedPageToday.
The alpha-1-adrenoreceptor antagonist failed to achieve any of the three primary endpoints of the trial, with no significant changes in PTSD symptoms after 10 weeks compared with placebo, according to Murray A. Raskind, MD, of the Veterans Affairs Puget Sound Health Care System in Seattle, and colleagues.with no significant changes in PTSD symptoms after 10 weeks compared with placebo, according to […]
